LYL-132 is under clinical development by Lyell Immunopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LYL-132’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LYL-132 is under development for the treatment solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1), synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCLS), non-small cell lung cancer. The therapeutic candidate comprises of T-cells genetically modified to express the T-cell receptor (TCR) targeting cells expressing cancer/testis antigen 1(NYESO-1). It is being developed based on epigenetic reprogramming (Epi-R) technology platform.
Lyell Immunopharma overview
Lyell Immunopharma (Lyell) is a biotechnology company developing cell-based immunotherapies for solid tumors and other cancers. It provides effective cell therapy is the profound understanding of the identity, fate, and function of cells to create living medicines. The company focuses on controlling and improving the differentiation and functionality of T cells armed with TCRs (T-cell receptor), CARs (chimeric antigen receptor), and other targeting modalities. Lyell ‘s effective cell therapy is the deep and profound understanding of the identity, fate and function of cells to create living medicines. The company operates an office in Seattle, Washington, the US. Lyell is headquartered in South San Francisco, California, the US.
For a complete picture of LYL-132’s drug-specific PTSR and LoA scores, buy the report here.